FDA Eases Rules for Non-Invasive Bone Healing Gadgets
Published Date: 4/16/2026
Rule
Summary
The FDA is changing the rules for non-invasive bone growth stimulators, moving them from the strictest category (Class III) to a less strict one (Class II) with special safety checks. This means companies can get these devices to market faster, but they still need to prove they’re safe and work well. The new rules kick in on May 18, 2026, affecting manufacturers and possibly speeding up patient access without extra costs.
Free Policy Watch
New rules are filed every week. Most people never see them.
Pick a topic. PRIA watches every federal rule and tells you when one hits your household.
Pick a topic to get started
Analyzed Economic Effects
6 provisions identified: 4 benefits, 2 costs, 0 mixed.
Manufacturers: Switch from PMA to 510(k)
If you make non‑invasive bone growth stimulators (product codes LOF and LPQ), the FDA reclassified them from class III to class II, so you may submit a 510(k) premarket notification instead of a PMA. This change is effective May 18, 2026 and typically shortens review time and lowers regulatory burden for bringing devices to market.
Faster Patient Access to Devices
The FDA expects the reclassification to enable more manufacturers to bring non‑invasive bone growth stimulators to market and to provide patients more timely access to these devices. The reclassification takes effect May 18, 2026.
Clinical Data Must Show Fusion Imaging
Manufacturers seeking clearance must provide clinical performance data and the final special control now requires that imaging data demonstrate fusion at the treatment site. This requirement applies to 510(k) submissions for these devices.
Non-Clinical Tests: Thermal, EMI, Reliability
The FDA established special controls requiring non-clinical performance testing, including verification/validation of thermal safety and thermal reliability, electromagnetic compatibility (EMC) testing for EMI risks, signal characterization within safe physiologic limits, and device reliability over expected use life. These tests must be included or demonstrated in support of 510(k) submissions.
No Extra Postmarket Surveillance Required
FDA declined the Panel's recommendation to require additional postmarket surveillance and will rely on standard postmarket requirements (e.g., medical device reporting). Manufacturers are not being required to conduct additional FDA‑mandated postmarket surveillance studies for these devices.
Labeling Must Warn About Implant Interference
The final order requires labeling special controls that include appropriate warnings for patients with implanted electrically powered devices and, where applicable, specify separation distances to reduce electromagnetic interference (EMI) risks. The labeling changes are part of the class II special controls.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in